Translational Research &Pharmacology Core Program Director/Principal Investigator: Gerson, Stanton L. PROJECT SUMMARY (See instructions): The primary role of the Translation Research &Pharmacology Core is to facilitate the implementation of scientifically rigorous correlative study components for Case CCC clinical trials. The Core has four components - a central office and cellular and molecular biology lab;a clinical processing lab;a clinical pharmacology lab;and a cancer pharmacology (mass spectrometry) lab. Core staff is composed of an experienced team dedicated to facilitating all aspects of the correlative study components of Case CCC clinical trials, guaranteeing consistent quality control. The TRC also includes an effort initially supported with UOl funds to perform in vitro testing of new drugs and combination therapies. The central, clinical processing and pharmacology labs are administered by the Case CCC, while the clinical pharmacology lab is managed through Cleveland Clinic, but is part of this Core operation. The service is to support correlative studies within Case CCC clinical trials. Support from the CCSG stabilizes the Core financially and provides clinical investigators formal ability to obtain clinical correlates. Formal access to Core services is extended to Case CCC members across the consortium sites. Services provided by the Core include: 1) consultation or full service writing of methods sections and budgets for CTEP letters of intent, protocols, and grants;2) sample informatics and correlate data;3) data analysis;4) sample handling (receiving, storage, distribution);5) sample processing (dispensing whole blood aliquots, routine blood processing, DNA, RNA and protein extraction, flow or laser scanning cytometry staining);6) lab analysis (western blots, ELISAs, MSD multiplex analysis, PARP activity and Poly(ADP)-ribose assay, comet assays);7) single or multiple agent cytotoxicity multiple agent analysis), 8) pharmacokinetic assay development, and 9) pharmacokinetic assay performance. The Core handles specimens from ~100 trials per year, members from all of the Case CCC Scientific Research Programs utilize the Core, and the user base is >95% Case CCC membership. The Core played a key role in numerous projects including: the first-in-human trial of the base excision inhibitor methoxyamine used in combination with temozolomide (Cancer Pharmacology Lab) and the design and operation ofthe Gl SPORE Biospecimen Core.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Brown, Amanda L; Mark Brown, J (2017) Critical roles for ?/? hydrolase domain 5 (ABHD5)/comparative gene identification-58 (CGI-58) at the lipid droplet interface and beyond. Biochim Biophys Acta 1862:1233-1241|
|Thiagarajan, Praveena S; Zheng, Qiao; Bhagrath, Manvir et al. (2017) STAT3 activation by leptin receptor is essential for TNBC stem cell maintenance. Endocr Relat Cancer 24:415-426|
|Yao, Peng; Wu, Jiangbin; Lindner, Daniel et al. (2017) Interplay between miR-574-3p and hnRNP L regulates VEGFA mRNA translation and tumorigenesis. Nucleic Acids Res 45:7950-7964|
|Donnola, Shannon B; Dasenbrook, Elliott C; Weaver, David et al. (2017) Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. J Cyst Fibros 16:283-290|
|Doherty, Mary R; Cheon, HyeonJoo; Junk, Damian J et al. (2017) Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proc Natl Acad Sci U S A 114:13792-13797|
|Saygin, Caner; Wiechert, Andrew; Rao, Vinay S et al. (2017) CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. J Exp Med 214:2715-2732|
|Samaeekia, Ravand; Adorno-Cruz, Valery; Bockhorn, Jessica et al. (2017) miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway. Clin Cancer Res 23:1091-1103|
|Flocke, Susan A; Hoffman, Richard; Eberth, Jan M et al. (2017) The Prevalence of Tobacco Use at Federally Qualified Health Centers in the United States, 2013. Prev Chronic Dis 14:E29|
|Balanis, Nikolas; Carlin, Cathleen R (2017) Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer. Mol Cell Endocrinol 451:24-30|
|Johansen, Mette L; Gao, Ying; Hutnick, Melanie A et al. (2017) Quantitative Molecular Imaging with a Single Gd-Based Contrast Agent Reveals Specific Tumor Binding and Retention in Vivo. Anal Chem 89:5932-5939|
Showing the most recent 10 out of 1182 publications